Chimeric antigen receptor T-cell therapy for aggressive B-cell lymphomas.

Chimeric antigen receptor (CAR) T-cell therapy is a revolutionary approach in the treatment of lymphoma. This review article provides an overview of the four FDA-approved CAR T-cell products for aggressive B-cell lymphoma, including diffuse large B-cell lymphoma and mantle cell lymphoma, highlighting their efficacy and toxicity as well as discussing future directions.
Competing Interests: BH participated on advisory board for Janssen Biotech and Pharmacyclics. Research funding to institution from BMS, Genentech/Roche, and Beigene. MP has received research funding and honorarium from BMS, Cellectar, Ceramedix, Juno, Kite MustangBio, Garuda Therapeutics, Novartis, Pluto Immunotherapeutics, Rheos, Seres Therapeutics, Smart Immune, Thymofox, Synthekine. Received other from June and Seres. The remaining author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
(Copyright © 2024 Hu, Korsos and Palomba.)